Alerts will be sent to your verified email
Verify Email
HESTERBIO
|
Hester Biosciences
|
NGL Fine-Chem
|
Solara Active Pharma
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceuticals
|
|||
|
R&D as a % of Total Sales
|
1.91 % | 1.8 % | n/a |
|
Financials
|
|||
|
5 yr Average ROE
|
11.06 % | 18.68 % | 2.8 % |
|
5yr average Equity Multiplier
|
2.16 | 1.37 | 1.99 |
|
5yr Average Asset Turnover Ratio
|
0.45 | 1.03 | 0.54 |
|
5yr Avg Net Profit Margin
|
11.7 % | 12.56 % | -7.28 % |
|
Price to Book
|
5.27 | 5.58 | 2.19 |
|
P/E
|
34.14 | 38.2 | 0.0 |
|
5yr Avg Cash Conversion Cycle
|
50.33 Days | 24.74 Days | 28.67 Days |
|
Inventory Days
|
95.01 Days | 47.94 Days | 111.94 Days |
|
Days Receivable
|
92.43 Days | 84.83 Days | 95.97 Days |
|
Days Payable
|
116.74 Days | 83.75 Days | 146.85 Days |
|
5yr Average Interest Coverage Ratio
|
6.83 | 25.7 | 0.25 |
|
5yr Avg ROCE
|
10.65 % | 24.83 % | 2.1 % |
|
5yr Avg Operating Profit Margin
|
21.24 % | 18.08 % | 9.63 % |
|
5 yr average Debt to Equity
|
0.76 | 0.16 | 0.7 |
|
5yr CAGR Net Profit
|
7.19 % | -18.08 % | -69.98 % |
|
5yr Average Return on Assets
|
5.25 % | 13.76 % | -3.67 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
53.73 % | 72.74 % | 42.0 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 31.57 % |
|
Change in Promoter Holding (3 Yrs)
|
0.0 | -0.79 % | 1.03 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | -1.03 % |
|
Hester Biosciences
|
NGL Fine-Chem
|
Solara Active Pharma
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
|
Distribution Channel
|
Distribution Channel
|
-
|
-
|
|
Operating Profit Break-Up
|
Operating Profit Break-Up
|
-
|
-
|
|
Capex
|
Capex
|
-
|
-
|
|
Asset Break-Up
|
Asset Break-Up
|
-
|
Asset Break-Up
|